Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer

Sungpil Yoon; Xiaoju Wang; Sompong Vongpunsawad; Gerard Tromp; Helena Kuivaniemi

doi:10.3389/fonc.2021.632657

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer

Front Oncol. 2021 Mar 17:11:632657. doi: 10.3389/fonc.2021.632657. eCollection 2021.

Authors

Sungpil Yoon¹, Xiaoju Wang², Sompong Vongpunsawad³, Gerard Tromp⁴, Helena Kuivaniemi⁴

Affiliations

¹ School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
² Department of Pathology, University of Michigan, Ann Arbor, MI, United States.
³ Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
⁴ Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University, Tygerberg, South Africa.

No abstract available

Keywords: MDR; P-gp overexpresssion; anticancer drug; cancer stem cell; drug repositioning; lower toxicity; molecular targeting; resistant cancer.

Publication types

Editorial